An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
NCT05420064 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000
Last updated 2025-11-12
Summary
The purpose of this study is to examine the impact of new cancer genetic counseling models that aim to increase patient engagement with the genetics team. To do this, the study consists of two trials to evaluate two related interventions. The first trial is the EfFORT Trial, which evaluates a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family. The study will look at how often genetic testing occurs when healthcare providers have permission to reach out to family members to recommend genetic testing and to help those who are interested get tested. The study will look at whether this cascade testing intervention is practical and effective. The study would like to see how this approach of healthcare providers reaching out directly to family members compares with the usual approach of patients telling their family members about the recommendation to get genetic testing. The second trial is the STRIVE Trial, which evaluates an intervention designed to help patients who receive an uncertain result from genetic testing (also called a "variant of uncertain significance") stay connected with their genetics care team, and to help patients and their primary care providers stay up-to-date about the meaning of uncertain genetic test results. The study will look at whether an intervention that consists of a study online portal for patients with uncertain genetic test results and their primary care providers will help them to stay up-to-date on the meaning of uncertain genetic test results. The study would like to see how this intervention compares to the usual approach of encouraging patients to re-contact their genetics care team on their own about a year after getting genetic testing."
Conditions
- BRCA1 Mutation
- POLD1 Gene Mutation
- CDKN2A Mutation
- BRCA2 Mutation
- POLE Gene Mutation
- APC Gene Mutation
- ATM Gene Mutation
- MLH1 Gene Mutation
- BARD1 Gene Mutation
- MSH2 Gene Mutation
- BRIP1 Gene Mutation
- MSH6 Gene Mutation
- CHEK2 Gene Mutation
- PMS2 Gene Mutation
- PALB2 Gene Mutation
- EPCAM Gene Mutation
- RAD51C Gene Mutation
- BMPR1A Gene Mutation
- RAD51D Gene Mutation
- SMAD4
- PTEN Gene Mutation
- GREM1
Interventions
- BEHAVIORAL
-
Intervention Arm At-risk Relative/ARR Contacts
Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
- BEHAVIORAL
-
MyGene Portal
Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.
- BEHAVIORAL
-
Standard of Care
Participants will received appropriate clinical care as outline by standard of care guidelines
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Kenneth Offit, MD, MPH · Memorial Sloan Kettering Cancer Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 25 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-12-01
- Primary Completion
- 2026-05-31
- Completion
- 2026-11-30
Countries
- United States
Study Locations
More Related Trials
-
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
NCT02917798 ·Status: ACTIVE_NOT_RECRUITING
-
A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
NCT02517554 ·Status: COMPLETED
-
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
NCT04902144 ·Status: COMPLETED ·Phase: NA
-
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
NCT05455606 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
NCT02470819 ·Status: WITHDRAWN ·Phase: NA
-
Prospective Registry of Multiplex Testing (PROMPT)
NCT02665195 ·Status: ACTIVE_NOT_RECRUITING
-
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
NCT05427240 ·Status: RECRUITING ·Phase: NA
-
Choices About Genetic Testing And Learning Your Risk With Smart Technology
NCT06184867 ·Status: COMPLETED ·Phase: NA
-
GENetic Education Risk Assessment and TEsting Study
NCT03762590 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
NCT04067960 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
NCT02823652 ·Status: COMPLETED ·Phase: NA
-
Michigan Genetic Hereditary Testing (MiGHT)
NCT05162846 ·Status: COMPLETED ·Phase: NA
-
Cancer Genetic Testing in Ethnic Populations
NCT04475640 ·Status: RECRUITING ·Phase: NA
-
Genetic Testing in Young Adults With Cancer Study
NCT04533555 ·Status: COMPLETED ·Phase: NA
-
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
NCT00003329 ·Status: COMPLETED
-
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
NCT06489041 ·Status: RECRUITING ·Phase: NA
-
Familial Investigations of Childhood Cancer Predisposition
NCT03050268 ·Status: RECRUITING
-
Physicians Survey on Genetic Testing
NCT00341107 ·Status: COMPLETED
-
Strategic Targeting for Optimal Prevention of Cancer
NCT03897374 ·Status: RECRUITING
-
Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy
NCT06060561 ·Status: SUSPENDED
-
Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study
NCT05772130 ·Status: RECRUITING ·Phase: NA
-
Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
NCT06927947 ·Status: RECRUITING ·Phase: NA
-
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
NCT00757614 ·Status: UNKNOWN
-
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935 ·Status: RECRUITING
-
Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
NCT05958082 ·Status: RECRUITING ·Phase: NA